Resmed’s AirFit masks appear to be boosting market share
Last November, Resmed launched its new range of AirFit masks. This led us to wonder if the uptick in growth in Resmed’s second quarter results was due to the new masks. Early indications are that the masks have been well received, and are increasing the company’s market share.
By way of background, Resmed was historically a market leader in masks but its previous mask range achieved relatively modest growth. This was due to a weaker reception by patients to user comfort and technological advances by its competitors.
While it’s early days, anecdotal feedback suggests that Resmed’s new mask range is being well received by physicians and patients. Importantly, it is faring well against Fisher & Paykel Healthcare whose masks have set the standard in recent years and taken meaningful share from the majors.
A key part of our investment thesis with Resmed is its potential to sell a higher number of consumables to its large customer base with these new products. It seems the number of consumables sold per customer has remained steady since the launch, but it will take time for existing customers to switch to the new masks as they’re accustomed to their current, older masks.
Resmed appears to be gaining further share over its major competitor, Philips Respironics, with both masks and flow generators during this quarter. While Respironics launched its DreamStation in late response to Resmed’s Airsense, it seems the Airsense remains a compelling value proposition for both distributors and customers. Resmed hasn’t discounted the prices of its new masks during this quarter, which is further evidence of a strong competitive position.
And finally, the underlying market appears to be growing in the mid-to-high single digits, so it is great for Resmed to be taking share in a rising market.
These anecdotal reports must be taken with a large grain of salt, as they comprise only a handful of participants in a global industry and quarterly assessments can be volatile. But broadly speaking, the trends appear positive.
Montgomery owns shares in Resmed.
This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.INVEST WITH MONTGOMERY